1
|
Thompson C, Bacha L, Paz PHC, de Assis Passos Oliveira M, Oliveira BCV, Omachi C, Chueke C, de Lima Hilário M, Lima M, Leomil L, Felix-Cordeiro T, da Cruz TLC, Otsuki K, Vidal L, Thompson M, Ribeiro E Silva R, Cabezas CMV, Veríssimo BM, Zaganelli JL, Botelho ACN, Teixeira L, Cosenza C, Costa PM, Landuci F, Tschoeke DA, Silva TA, Attias M, de Souza W, de Rezende CE, Thompson F. Collapse of scallop Nodipecten nodosus production in the tropical Southeast Brazil as a possible consequence of global warming and water pollution. Sci Total Environ 2023; 904:166873. [PMID: 37689208 DOI: 10.1016/j.scitotenv.2023.166873] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Revised: 09/01/2023] [Accepted: 09/04/2023] [Indexed: 09/11/2023]
Abstract
Mollusc rearing is a relevant global socioeconomic activity. However, this activity has faced severe problems in the last years in southeast Brazil. The mariculture scallop production dropped from 51,2 tons in 2016 to 10,2 tons in 2022 in the Baia da Ilha Grande (BIG; Rio de Janeiro). However, the possible causes of this collapse are unknown. This study aimed to analyze decadal trends of water quality in Nodipecten nodosus spat and adult production in BIG. We also performed physical-chemical and biological water quality analyses of three scallop farms and two nearby locations at BIG in 2022 to evaluate possible environmental stressors and risks. Scallop spat production dropped drastically in the last five years (2018-2022: mean ± stdev: 0.47 ± 0.45 million). Spat production was higher in colder waters and during peaks of Chlorophyll a in the last 13 years. Reduction of Chlorophyll a coincided with decreasing spat production in the last five years. Warmer periods (>27 °C) of the year may hamper scallop development. Counts of potentially pathogenic bacteria (Vibrios) and Escherichia coli were significantly higher in warmer periods which may further reduce scallop productivity. Shotgun metagenomics of seawater samples from the five studied corroborated these culture-based counts. Vibrios and fecal indicator bacteria metagenomic sequences were abundant across the entire study area throughout 2022. The results of this study suggest the collapse of scallop mariculture is the result of a synergistic negative effect of global warming and poor seawater quality.
Collapse
Affiliation(s)
- Cristiane Thompson
- Laboratory of Microbiology, Institute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.
| | - Leonardo Bacha
- Laboratory of Microbiology, Institute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil; Fuzzy Lab, Politécnica, UFRJ, Rio de Janeiro, Brazil
| | - Pedro Henrique C Paz
- Laboratory of Microbiology, Institute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | | | - Braulio Cherene Vaz Oliveira
- Laboratory of Environmental Sciences (LCA), Center of Biosciences and Biotechnology (CBB), State University of Northern of Rio de Janeiro Darcy Ribeiro (UENF), Campos dos Goytacazes, Brazil
| | - Claudia Omachi
- Laboratory of Microbiology, Institute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | - Caroline Chueke
- Laboratory of Microbiology, Institute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | - Marcela de Lima Hilário
- Laboratory of Microbiology, Institute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | - Michele Lima
- Laboratory of Microbiology, Institute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | - Luciana Leomil
- Laboratory of Microbiology, Institute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | - Thais Felix-Cordeiro
- Laboratory of Microbiology, Institute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | - Thalya Lou Cordeiro da Cruz
- Laboratory of Microbiology, Institute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | - Koko Otsuki
- Laboratory of Microbiology, Institute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | - Livia Vidal
- Laboratory of Microbiology, Institute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | - Mateus Thompson
- Laboratory of Microbiology, Institute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil; Fisheries Institute of the Rio de Janeiro State (FIPERJ), Niterói, Brazil
| | - Renan Ribeiro E Silva
- Instituto de Sócio Desenvolvimento da Baia da Ilha Grande (IED-BIG), Angra dos Reis, Brazil
| | | | - Bruno Marque Veríssimo
- Instituto de Sócio Desenvolvimento da Baia da Ilha Grande (IED-BIG), Angra dos Reis, Brazil
| | - José Luiz Zaganelli
- Instituto de Sócio Desenvolvimento da Baia da Ilha Grande (IED-BIG), Angra dos Reis, Brazil
| | - Ana Caroline N Botelho
- Institute of Microbiology Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| | - Lucia Teixeira
- Institute of Microbiology Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| | | | - Paulo Marcio Costa
- Fisheries Institute of the Rio de Janeiro State (FIPERJ), Niterói, Brazil
| | - Felipe Landuci
- Fisheries Institute of the Rio de Janeiro State (FIPERJ), Niterói, Brazil
| | - Diogo A Tschoeke
- Laboratory of Microbiology, Institute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil; Biomedical Engineer Program, COPPE, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | | | - Marcia Attias
- Laboratory of Cell Ultrastructure Hertha Meyer (CENABIO), UFRJ, Brazil
| | | | - Carlos E de Rezende
- Laboratory of Environmental Sciences (LCA), Center of Biosciences and Biotechnology (CBB), State University of Northern of Rio de Janeiro Darcy Ribeiro (UENF), Campos dos Goytacazes, Brazil
| | - Fabiano Thompson
- Laboratory of Microbiology, Institute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.
| |
Collapse
|
2
|
Gutierrez-Ontalvilla P, Vidal L, Ruiz-Valls A, Iborra M. Letter to the Editor on The Effect of Lipofilling and Platelet-Rich Plasma on Patients with Moderate-Severe Vulvar Lichen Sclerosus who were Non-Responders to Topical Clobetasol Propionate: A Randomized Pilot Study. Aesthetic Plast Surg 2023; 47:66-68. [PMID: 35689103 DOI: 10.1007/s00266-022-02960-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2022] [Accepted: 05/17/2022] [Indexed: 11/01/2022]
Affiliation(s)
- P Gutierrez-Ontalvilla
- Department of Plastic and Reconstructive Surgery, Hospital University La Fe, Avda Fernando Abril Martorell 106, 46026, Valencia, Spain.
| | - L Vidal
- Fidia Farmacéutica S.L.U, Barcelona, Spain
| | - A Ruiz-Valls
- Department of Plastic and Reconstructive Surgery, Hospital University La Fe, Avda Fernando Abril Martorell 106, 46026, Valencia, Spain
| | - M Iborra
- Unit of Inflammatory Bowel Disease, Department of Digestive Medicine, Hospital University La Fe, Valencia, Spain
| |
Collapse
|
3
|
Gutierrez-Ontalvilla P, Giner F, Vidal L, Iborra M. The Effect of Lipofilling and Platelet-Rich Plasma on Patients with Moderate-Severe Vulvar Lichen Sclerosus who were Non-Responders to Topical Clobetasol Propionate: A Randomized Pilot Study. Aesthetic Plast Surg 2022; 46:2469-2479. [PMID: 35048150 DOI: 10.1007/s00266-021-02718-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2021] [Accepted: 12/06/2021] [Indexed: 12/24/2022]
Abstract
BACKGROUND The first-line treatment for vulvar lichen sclerosus (VLS) is 3 months of topical corticosteroid therapy. However, limited evidence is available concerning the use of fat grafting and platelet-rich plasma as a second-line treatment for patients who do not respond to first-line treatment. METHODS This prospective single-center randomized pilot trial included 20 patients with a clinical and histological diagnosis of moderate to severe VLS. The patients in the treatment group (TG) received two infiltrations (at 3-month intervals) of nanofat mixed with platelet-rich plasma (PRP) into the vulvar area, while the control group (CG) received standard topical corticosteroid therapy. Fat was aspirated from the medial thigh or lower abdomen regions. Microfat was obtained after centrifugation and was emulsified to obtain a nanofat suspension. Treatment efficacy was determined by measuring changes in the vulvar skin elasticity, histopathology, and clinical signs, symptoms, and patient quality of life at after 1 year. RESULTS A total of 19 patients were finally assessed (9 TG and 10 CG). At the end of the study (1 year), there had been no significant improvement in vulvar skin elasticity. However, patients in the TG showed a significant improvement in their symptoms (itching, pain, burning, and dyspareunia) and clinical signs (cervical erosions, fissures, stenosis, and leukoderma). Analysis of skin biopsies revealed a significant decrease in all inflammatory cell types in the TG. No adverse events related to the autologous treatment were recorded. CONCLUSIONS Compared with topical corticosteroids, two infiltrations delivered 3 months apart decreased the inflammation of the vulva and improved most of the clinical signs and symptoms associated with VLS. Nonetheless, no improvement in vulvar skin elasticity was derived from the autologous treatment. LEVEL OF EVIDENCE I This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Collapse
Affiliation(s)
- P Gutierrez-Ontalvilla
- Department of Plastic and Reconstructive Surgery, Hospital University La Fe, Avda Fernando Abril Martorell 106, 46026, Valencia, Spain.
| | - F Giner
- Department of Histology, Hospital University La Fe, Valencia, Spain
| | - L Vidal
- Fidia Farmacéutica S.L.U, Barcelona, Spain
| | - M Iborra
- Department of Digestive Medicine, Unit of inflammatory bowel disease, Hospital University La Fe, Valencia, Spain
| |
Collapse
|
4
|
Frenel JS, Kim JW, Aryal N, Asher R, Berton D, Vidal L, Pautier P, Ledermann JA, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Colombo N, Park-Simon TW, Tamura K, Sonke GS, Freimund AE, Lee CK, Pujade-Lauraine E. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial. Ann Oncol 2022; 33:1021-1028. [PMID: 35772665 DOI: 10.1016/j.annonc.2022.06.011] [Citation(s) in RCA: 43] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2022] [Revised: 06/16/2022] [Accepted: 06/20/2022] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND In the SOLO2 trial (ENGOT Ov-21; NCT01874353), maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer (PSROC) and BRCA mutation significantly improved progression-free survival (PFS) and prolonged overall survival (OS). Following disease progression on olaparib, efficacy of subsequent chemotherapy remains unknown. PATIENTS AND METHODS We conducted a post-hoc hypothesis-generating analysis of SOLO2 data to determine the efficacy of different chemotherapy regimens following RECIST disease progression in patients who received olaparib or placebo. We evaluated time to second progression (TTSP) calculated from the date of RECIST progression to the next progression/death. RESULTS The study population comprised 147 patients who received chemotherapy as their first subsequent treatment after RECIST progression. Of these, 69 (47%) and 78 (53%) were originally randomized to placebo and olaparib arms, respectively. In the placebo-treated cohort, 27/69 and 42/69 received non-platinum and platinum-based chemotherapy, respectively, compared with 24/78 and 54/78, respectively, in the olaparib-treated cohort. Among patients treated with chemotherapy (N = 147), TTSP was significantly longer in the placebo than in the olaparib arm: 12.1 versus 6.9 months [hazard ratio (HR) 2.17, 95% confidence interval (CI) 1.47-3.19]. Similar result was obtained on multivariable analysis adjusting for prognostic factors at RECIST progression (HR 2.13, 95% CI 1.41-3.22). Among patients treated with platinum-based chemotherapy (n = 96), TTSP was significantly longer in the placebo arm: 14.3 versus 7.0 months (HR 2.89, 95% CI 1.73-4.82). Conversely, among patients treated with non-platinum-based chemotherapy (n = 51), the TTSP was comparable in the placebo and olaparib arms: 8.3 versus 6.0 months (HR 1.58, 95% CI 0.86-2.90). CONCLUSIONS Following progression from maintenance olaparib in the recurrent setting, the efficacy of platinum-based subsequent chemotherapy seems to be reduced in BRCA1/2-mutated patients with PSROC compared to patients not previously receiving poly (ADP-ribose) polymerase inhibitors (PARPi). The optimal strategy for patients who relapse after PARPi is an area of ongoing research.
Collapse
Affiliation(s)
- J S Frenel
- Institut de Cancerologie de l'Ouest, GINECO, GINEGEPS, Centre René Gauducheau, Saint-Herblain, France.
| | - J W Kim
- Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - N Aryal
- NHMRC CTC Centre, University of Sydney, Camperdown, Sydney, Australia
| | - R Asher
- NHMRC CTC Centre, University of Sydney, Camperdown, Sydney, Australia
| | - D Berton
- Institut de Cancerologie de l'Ouest, GINECO, GINEGEPS, Centre René Gauducheau, Saint-Herblain, France
| | - L Vidal
- GEICO & H Clínic de Barcelona, Barcelona, Spain
| | - P Pautier
- GINECO & Gustave Roussy Cancer Center, Villejuif, France
| | | | - R T Penson
- Massachusetts General Hospital, Boston, USA
| | - A M Oza
- Princess Margaret Cancer Centre, Toronto, Canada
| | - J Korach
- ISGO & Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel
| | - T Huzarski
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - S Pignata
- MITO & Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Napoli, Naples, Italy
| | - N Colombo
- MaNGO & European Institute of Oncology IRCCS and University of Milan-Bicocca, Milano, Italy
| | - T W Park-Simon
- AGO & Medical School, Department of Gynecologic Oncology, Hannover, Hannover, Germany
| | - K Tamura
- Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - G S Sonke
- DGOG & Netherlands Cancer Institute, Amsterdam, Netherlands
| | - A E Freimund
- Peter MacCallum Cancer Centre, Melbourne, Australia
| | - C K Lee
- NHMRC CTC Centre, University of Sydney, Camperdown, Sydney, Australia
| | | |
Collapse
|
5
|
Montazeri S, De la Garza-Ramos C, Lewis A, Lewis J, LeGout J, Sella D, Paz-Fumagalli R, Devcic Z, Ritchie C, Frey G, Vidal L, McKinney J, Toskich B. Abstract No. 197 Predictors of complete pathologic necrosis in hepatocellular carcinoma treated with yttrium-90 radiation segmentectomy prior to liver transplantation: an explant analysis of 75 tumors. J Vasc Interv Radiol 2022. [DOI: 10.1016/j.jvir.2022.03.278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
6
|
O'Kelly B, Vidal L, Avramovic G, Broughan J, Cotter AG, Cullen W, McHugh T, O'Gorman T, Woo J, Lambert JS. Predictors and Outcomes for COVID-19 Re-Admissions in the Anticipate Cohort. Ir Med J 2022; 115:599. [PMID: 35696289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Aims To describe readmissions of hospitalised patients with COVID-19, define predictors of readmission and explore the long term outcomes using the SF-12 score compared to patients who were not readmitted and those not hospitalised. Methods A single centre retrospective in North Inner-City Dublin. Recruitment was done through a COVID follow up clinic. Predictors of readmission and SF-12 scores at two timepoints post follow up at median 3 months and 12 months. Results Seventy (45%) participants were admitted, with a median age of 49.5 years (IQR 41.3-56.9), 36(51%) of whom were female. Unscheduled readmissions at ≤30 days in COVID-19 patients were 9(12.9%) and length of stay was four days (IQR 2-5). Readmissions were due to ongoing symptoms(n=9(64.3%)) or new complications(n=5(35.7%)). Mechanical ventilation and having symptoms of nausea and vomiting on index admission were predictive of readmission. (p=0.002). SF-12 scores at one year of readmitted patients were not different to patients who were never admitted at median one year follow up, p=.089. Conclusions Most readmissions were of short duration. Early follow up of patients post MV or who had nausea and vomiting on index admission should be prioritised. Wellbeing of readmitted patients was not different to those never hospitalised, at one year.
Collapse
Affiliation(s)
- B O'Kelly
- Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin 7, Ireland
- Centre for Experimental Pathogen Host Research, University College Dublin, Dublin 4, Ireland
| | - L Vidal
- School of Medicine, University College Dublin, Dublin 4, Ireland
| | - G Avramovic
- School of Medicine, University College Dublin, Dublin 4, Ireland
| | - J Broughan
- School of Medicine, University College Dublin, Dublin 4, Ireland
| | - A G Cotter
- Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin 7, Ireland
- Centre for Experimental Pathogen Host Research, University College Dublin, Dublin 4, Ireland
- School of Medicine, University College Dublin, Dublin 4, Ireland
| | - W Cullen
- School of Medicine, University College Dublin, Dublin 4, Ireland
| | - T McHugh
- School of Medicine, University College Dublin, Dublin 4, Ireland
| | - T O'Gorman
- School of Medicine, University College Dublin, Dublin 4, Ireland
| | - J Woo
- Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin 7, Ireland
| | - J S Lambert
- Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin 7, Ireland
- School of Medicine, University College Dublin, Dublin 4, Ireland
| |
Collapse
|
7
|
Chetcuti K, Chilingulo C, Goyal MS, Vidal L, O'Brien NF, Postels DG, Seydel KB, Taylor TE. Implementation of a Low-Field Portable MRI Scanner in a Resource-Constrained Environment: Our Experience in Malawi. AJNR Am J Neuroradiol 2022; 43:670-674. [PMID: 35450856 PMCID: PMC9089250 DOI: 10.3174/ajnr.a7494] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Accepted: 03/03/2022] [Indexed: 11/07/2022]
Abstract
Low-field, portable MR imaging may expedite patient management in the setting of critical illness. We successfully implemented low-field MR imaging at the Queen Elizabeth Central Hospital in Malawi; a low-resource setting. We present our experience of low-field, portable MR imaging start-up and use in Malawi; the first of its kind in Sub-Saharan Africa, together with complementary troubleshooting mechanisms that may be used especially in similar resource-constrained contexts.
Collapse
Affiliation(s)
- K Chetcuti
- From the Department of Paediatrics and Child Health (K.C.)
| | - C Chilingulo
- Blantyre Malaria Project (C.C., N.F.O., D.G.P., K.B.S., T.E.T.), Kamuzu University of Health Sciences, Blantyre, Malawi.,Department of Radiology (C.C.), Queen Elizabeth Central Hospital, Blantyre, Malawi
| | - M S Goyal
- Mallinckrodt Institute of Radiology (M.S.G.), Washington University School of Medicine, St. Louis, Missouri
| | - L Vidal
- Division of Neuroradiology (L.V.), Department of Radiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
| | - N F O'Brien
- Blantyre Malaria Project (C.C., N.F.O., D.G.P., K.B.S., T.E.T.), Kamuzu University of Health Sciences, Blantyre, Malawi.,Division of Critical Care Medicine (N.F.O.), Department of Pediatrics, Nationwide Children's Hospital, Ohio State University, Columbus, Ohio
| | - D G Postels
- Blantyre Malaria Project (C.C., N.F.O., D.G.P., K.B.S., T.E.T.), Kamuzu University of Health Sciences, Blantyre, Malawi.,Department of Neurology (D.G.P.), George Washington University/Children's National Medical Center, Washington, DC
| | - K B Seydel
- Blantyre Malaria Project (C.C., N.F.O., D.G.P., K.B.S., T.E.T.), Kamuzu University of Health Sciences, Blantyre, Malawi.,Department of Osteopathic Medical Specialties (K.B.S., T.E.T.), College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan
| | - T E Taylor
- Blantyre Malaria Project (C.C., N.F.O., D.G.P., K.B.S., T.E.T.), Kamuzu University of Health Sciences, Blantyre, Malawi.,Department of Osteopathic Medical Specialties (K.B.S., T.E.T.), College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan
| |
Collapse
|
8
|
Alcántara I, Somma A, Chalar G, Fabre A, Segura A, Achkar M, Arocena R, Aubriot L, Baladán C, Barrios M, Bonilla S, Burwood M, Calliari DL, Calvo C, Capurro L, Carballo C, Céspedes-Payret C, Conde D, Corrales N, Cremella B, Crisci C, Cuevas J, De Giacomi S, De León L, Delbene L, Díaz I, Fleitas V, González-Bergonzoni I, González-Madina L, González-Piana M, Goyenola G, Gutiérrez O, Haakonsson S, Iglesias C, Kruk C, Lacerot G, Langone J, Lepillanca F, Lucas C, Martigani F, Martínez de la Escalera G, Meerhoff M, Nogueira L, Olano H, Pacheco JP, Panario D, Piccini C, Quintans F, Teixeira de Mello F, Terradas L, Tesitore G, Vidal L, García-Rodríguez F. A reply to "Relevant factors in the eutrophication of the Uruguay River and the Río Negro". Sci Total Environ 2022; 818:151854. [PMID: 34826482 DOI: 10.1016/j.scitotenv.2021.151854] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/24/2021] [Revised: 11/02/2021] [Accepted: 11/17/2021] [Indexed: 06/13/2023]
Abstract
A recent paper by Beretta-Blanco and Carrasco-Letelier (2021) claims that agricultural eutrophication is not one of the main causes for cyanobacterial blooms in rivers and artificial reservoirs. By combining rivers of markedly different hydrological characteristics e.g., presence/absence and number of dams, river discharge and geological setting, the study speculates about the role of nutrients for modulating phytoplankton chlorophyll-a. Here, we identified serious flaws, from erratic and inaccurate data manipulation. The study did not define how erroneous original dataset values were treated, how the variables below the detection/quantification limit were numerically introduced, lack of mandatory variables for river studies such as flow and rainfall, arbitrary removal of pH > 7.5 values (which were not outliers), and finally how extreme values of other environmental variables were included. In addition, we identified conceptual and procedural mistakes such as biased construction/evaluation of model prediction capability. The study trained the model using pooled data from a short restricted lotic section of the (large) Uruguay River and from both lotic and reservoir domains of the Negro River, but then tested predictability within the (small) Cuareim River. Besides these methodological considerations, the article shows misinterpretations of the statistical correlation of cause and effect neglecting basic limnological knowledge of the ecology of harmful algal blooms (HABs) and international research on land use effects on freshwater quality. The argument that pH is a predictor variable for HABs neglects overwhelming basic paradigms of carbon fluxes and change in pH because of primary productivity. As a result, the article introduces the notion that HABs formation are not related to agricultural land use and water residence time and generate a great risk for the management of surface waterbodies. This reply also emphasizes the need for good practices of open data management, especially for public databases in view of external reproducibility.
Collapse
Affiliation(s)
- I Alcántara
- Ud. Bioestadística, Departamento de Salud Pública, Facultad de Veterinaria, Universidad de la República, Montevideo, Uruguay
| | - A Somma
- Polo de Ecología Fluvial, CENUR Litoral Norte sede Paysandú, Universidad de la República, Paysandú, Uruguay; Unidad Usinas de Montevideo, Área Tratamiento - Obras Sanitarias del Estado, Aguas Corrientes, Canelones, Uruguay
| | - G Chalar
- Sección Limnología, IECA, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay
| | - A Fabre
- ITR Suroeste, Universidad Tecnológica, La Paz, Colonia, Uruguay
| | - A Segura
- Modelización y Análisis de Recursos Naturales, Centro Universitario Regional del Este, Universidad de la República, Rocha, Uruguay
| | - M Achkar
- LDSGAT, IECA, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| | - R Arocena
- Sección Limnología, IECA, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay
| | - L Aubriot
- Sección Limnología, IECA, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay
| | - C Baladán
- Departamento de Ecología y Gestión Ambiental, Centro Universitario Regional del Este, Universidad de la República, Maldonado, Uruguay
| | - M Barrios
- Departamento de Ecología y Gestión Ambiental, Centro Universitario Regional del Este, Universidad de la República, Maldonado, Uruguay
| | - S Bonilla
- Sección Limnología, IECA, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay
| | - M Burwood
- Departamento de Ecología y Gestión Ambiental, Centro Universitario Regional del Este, Universidad de la República, Maldonado, Uruguay
| | - D L Calliari
- Sección Oceanografía y Ecología Marina, IECA, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| | - C Calvo
- Departamento de Ecología y Gestión Ambiental, Centro Universitario Regional del Este, Universidad de la República, Maldonado, Uruguay
| | - L Capurro
- Sección Limnología, IECA, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay
| | - C Carballo
- Sección Limnología, IECA, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay
| | - C Céspedes-Payret
- UNCIEP, IECA, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| | - D Conde
- Sección Limnología, IECA, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay
| | - N Corrales
- Sección Limnología, IECA, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay
| | - B Cremella
- Laboratory of Environmental Analysis, Université de Sherbrooke, Sherbrooke, Quebec, Canada
| | - C Crisci
- Modelización y Análisis de Recursos Naturales, Centro Universitario Regional del Este, Universidad de la República, Rocha, Uruguay
| | - J Cuevas
- Sección Limnología, IECA, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay
| | - S De Giacomi
- Sección Limnología, IECA, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay
| | - L De León
- Ministerio de Ambiente - Dirección Nacional de Calidad y Evaluación Ambiental, Uruguay
| | - L Delbene
- Sección Limnología, IECA, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay
| | - I Díaz
- LDSGAT, IECA, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| | - V Fleitas
- Departamento de Ecología y Gestión Ambiental, Centro Universitario Regional del Este, Universidad de la República, Maldonado, Uruguay
| | - I González-Bergonzoni
- Polo de Ecología Fluvial, CENUR Litoral Norte sede Paysandú, Universidad de la República, Paysandú, Uruguay
| | - L González-Madina
- Departamento de Ecología y Gestión Ambiental, Centro Universitario Regional del Este, Universidad de la República, Maldonado, Uruguay; Unidad Usinas de Montevideo, Área Tratamiento - Obras Sanitarias del Estado, Aguas Corrientes, Canelones, Uruguay
| | - M González-Piana
- Sección Limnología, IECA, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay
| | - G Goyenola
- Departamento de Ecología y Gestión Ambiental, Centro Universitario Regional del Este, Universidad de la República, Maldonado, Uruguay
| | - O Gutiérrez
- UNCIEP, IECA, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| | - S Haakonsson
- Sección Limnología, IECA, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay
| | - C Iglesias
- Departamento de Ecología y Gestión Ambiental, Centro Universitario Regional del Este, Universidad de la República, Maldonado, Uruguay
| | - C Kruk
- Sección Limnología, IECA, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay; Modelización y Análisis de Recursos Naturales, Centro Universitario Regional del Este, Universidad de la República, Rocha, Uruguay
| | - G Lacerot
- Ecología Funcional de Sistemas Acuáticos, Centro Universitario Regional del Este, Universidad de la República, Uruguay
| | - J Langone
- Unidad Usinas de Montevideo, Área Tratamiento - Obras Sanitarias del Estado, Aguas Corrientes, Canelones, Uruguay
| | - F Lepillanca
- Departamento de Microbiología, Instituto de Investigaciones Biológicas Clemente Estable, Ministerio de Educación y Cultura, Montevideo, Uruguay
| | - C Lucas
- Polo de Ecología Fluvial, CENUR Litoral Norte sede Paysandú, Universidad de la República, Paysandú, Uruguay
| | - F Martigani
- Área Hidrobiología, Gerencia de Gestión de Laboratorios, OSE, Montevideo, Uruguay
| | - G Martínez de la Escalera
- Departamento de Microbiología, Instituto de Investigaciones Biológicas Clemente Estable, Ministerio de Educación y Cultura, Montevideo, Uruguay
| | - M Meerhoff
- Departamento de Ecología y Gestión Ambiental, Centro Universitario Regional del Este, Universidad de la República, Maldonado, Uruguay; Department of Biosciences, Aarhus University, Silkeborg, Denmark
| | - L Nogueira
- Unidad Usinas de Montevideo, Área Tratamiento - Obras Sanitarias del Estado, Aguas Corrientes, Canelones, Uruguay
| | - H Olano
- Sección Limnología, IECA, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay
| | - J P Pacheco
- Departamento de Ecología y Gestión Ambiental, Centro Universitario Regional del Este, Universidad de la República, Maldonado, Uruguay
| | - D Panario
- UNCIEP, IECA, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| | - C Piccini
- Departamento de Microbiología, Instituto de Investigaciones Biológicas Clemente Estable, Ministerio de Educación y Cultura, Montevideo, Uruguay
| | - F Quintans
- Sección Limnología, IECA, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay
| | - F Teixeira de Mello
- Departamento de Ecología y Gestión Ambiental, Centro Universitario Regional del Este, Universidad de la República, Maldonado, Uruguay
| | - L Terradas
- UNCIEP, IECA, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| | - G Tesitore
- Departamento de Ecología y Gestión Ambiental, Centro Universitario Regional del Este, Universidad de la República, Maldonado, Uruguay
| | - L Vidal
- Área Hidrobiología, Gerencia de Gestión de Laboratorios, OSE, Montevideo, Uruguay
| | - F García-Rodríguez
- Departamento de Geociencias, Centro Universitario Regional del Este, Universidad de la República, Rocha, Uruguay; Instituto de Oceanografia, Universidade Federal do Rio Grande (FURG), Rio Grande, Brazil.
| |
Collapse
|
9
|
Todorova S, Blin J, Naydenov A, Lebeau B, Karashanova D, Kolev H, Gaudin P, Velinova R, Vidal L, Michelin L, Josien L, Filkova D, Ivanova I, Dotzeva A, Tenchev K. Co-Mn oxides supported on hierarchical macro-mesoporous silica for CO and VOCs oxidation. Catal Today 2021. [DOI: 10.1016/j.cattod.2020.01.019] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
10
|
Todorova S, Blin J, Naydenov A, Lebeau B, Kolev H, Gaudin P, Dotzeva A, Velinova R, Filkova D, Ivanova I, Vidal L, Michelin L, Josien L, Tenchev K. Co3O4-MnOx oxides supported on SBA-15 for CO and VOCs oxidation. Catal Today 2020. [DOI: 10.1016/j.cattod.2019.05.018] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
11
|
Tschoeke D, Salazar VW, Vidal L, Campeão M, Swings J, Thompson F, Thompson C. Unlocking the Genomic Taxonomy of the Prochlorococcus Collective. Microb Ecol 2020; 80:546-558. [PMID: 32468160 DOI: 10.1007/s00248-020-01526-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/13/2020] [Accepted: 05/07/2020] [Indexed: 06/11/2023]
Abstract
Prochlorococcus is the most abundant photosynthetic prokaryote on our planet. The extensive ecological literature on the Prochlorococcus collective (PC) is based on the assumption that it comprises one single genus comprising the species Prochlorococcus marinus, containing itself a collective of ecotypes. Ecologists adopt the distributed genome hypothesis of an open pan-genome to explain the observed genomic diversity and evolution patterns of the ecotypes within PC. Novel genomic data for the PC prompted us to revisit this group, applying the current methods used in genomic taxonomy. As a result, we were able to distinguish the five genera: Prochlorococcus, Eurycolium, Prolificoccus, Thaumococcus, and Riococcus. The novel genera have distinct genomic and ecological attributes.
Collapse
Affiliation(s)
- Diogo Tschoeke
- Laboratory of Microbiology, SAGE-COPPE and Institute of Biology, Federal University of Rio de Janeiro, Av. Carlos Chagas Fo 373, Rio de Janeiro, RJ, 21941-902, Brazil
| | - Vinicius W Salazar
- Laboratory of Microbiology, SAGE-COPPE and Institute of Biology, Federal University of Rio de Janeiro, Av. Carlos Chagas Fo 373, Rio de Janeiro, RJ, 21941-902, Brazil
| | - Livia Vidal
- Laboratory of Microbiology, SAGE-COPPE and Institute of Biology, Federal University of Rio de Janeiro, Av. Carlos Chagas Fo 373, Rio de Janeiro, RJ, 21941-902, Brazil
| | - Mariana Campeão
- Laboratory of Microbiology, SAGE-COPPE and Institute of Biology, Federal University of Rio de Janeiro, Av. Carlos Chagas Fo 373, Rio de Janeiro, RJ, 21941-902, Brazil
| | - Jean Swings
- Laboratory of Microbiology, SAGE-COPPE and Institute of Biology, Federal University of Rio de Janeiro, Av. Carlos Chagas Fo 373, Rio de Janeiro, RJ, 21941-902, Brazil
- Laboratory of Microbiology, Ghent University, Gent, Belgium
| | - Fabiano Thompson
- Laboratory of Microbiology, SAGE-COPPE and Institute of Biology, Federal University of Rio de Janeiro, Av. Carlos Chagas Fo 373, Rio de Janeiro, RJ, 21941-902, Brazil
| | - Cristiane Thompson
- Laboratory of Microbiology, SAGE-COPPE and Institute of Biology, Federal University of Rio de Janeiro, Av. Carlos Chagas Fo 373, Rio de Janeiro, RJ, 21941-902, Brazil.
| |
Collapse
|
12
|
Frenel JS, Kim JW, Berton-Rigaud D, Asher R, Vidal L, Pautier P, Ledermann J, Penson R, Oza A, Korach J, Huzarski T, Pignata S, Colombo N, Park-Simon TW, Tamura K, Sonke G, Freimund A, Lee C, Pujade-Lauraine E. 813MO Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO2/ENGOT Ov-21 trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.952] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
13
|
Azevedo GPR, Mattsson HK, Lopes GR, Vidal L, Campeão M, Tonon LAC, Garcia GD, Tschoeke DA, Silva BS, Otsuki K, Gomez-Gil B, Swings J, Thompson FL, Thompson CC. Vibrio tetraodonis sp. nov.: genomic insights on the secondary metabolites repertoire. Arch Microbiol 2020; 203:399-404. [PMID: 32844278 DOI: 10.1007/s00203-020-02019-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Revised: 07/30/2020] [Accepted: 08/08/2020] [Indexed: 11/26/2022]
Abstract
Description of a Gram-negative, motile, circular-shaped bacterial strain, designated A511T obtained from the skin of the pufferfish Sphoeroides spengleri (Family Tetraodontidae), collected in Arraial do Cabo, Brazil. Optimum growth occurs at 20-28 °C in the presence of 3% NaCl. The genome sequence of the novel isolate consisted of 4.36 Mb, 3,976 coding genes and G + C content of 42.5%. Genomic taxonomy analyses based on average amino acid (AAI), genome-to-genome-distance (GGDH) and phylogenetic reconstruction placed A511T (= CBAS 712T = CAIM 1939T) into a new species of the genus Vibrio (Vibrio tetraodonis sp. nov.). The genome of the novel species contains eight genes clusters (~ 183.9 Kbp in total) coding for different types of bioactive compounds that hint to several possible ecological roles in the pufferfish host.
Collapse
Affiliation(s)
- Gustavo P R Azevedo
- Institute of Biology and SAGE-COPPE, Federal University of Rio de Janeiro, Avenida Carlos Chagas Fo, s/n, Bloco A, Ilha do Fundão, Rio de Janeiro, RJ, CEP 21941-590, Brazil.
| | - Hannah K Mattsson
- Institute of Biology and SAGE-COPPE, Federal University of Rio de Janeiro, Avenida Carlos Chagas Fo, s/n, Bloco A, Ilha do Fundão, Rio de Janeiro, RJ, CEP 21941-590, Brazil
| | - Grasiele R Lopes
- Institute of Biology and SAGE-COPPE, Federal University of Rio de Janeiro, Avenida Carlos Chagas Fo, s/n, Bloco A, Ilha do Fundão, Rio de Janeiro, RJ, CEP 21941-590, Brazil
| | - Livia Vidal
- Institute of Biology and SAGE-COPPE, Federal University of Rio de Janeiro, Avenida Carlos Chagas Fo, s/n, Bloco A, Ilha do Fundão, Rio de Janeiro, RJ, CEP 21941-590, Brazil
| | - Mariana Campeão
- Institute of Biology and SAGE-COPPE, Federal University of Rio de Janeiro, Avenida Carlos Chagas Fo, s/n, Bloco A, Ilha do Fundão, Rio de Janeiro, RJ, CEP 21941-590, Brazil
| | - Luciane A Chimetto Tonon
- Instituto de Química de São Carlos, Universidade de São Paulo, CP 780, São Carlos, SP, CEP 13560-970, Brazil
| | - Gizele D Garcia
- Institute of Biology and SAGE-COPPE, Federal University of Rio de Janeiro, Avenida Carlos Chagas Fo, s/n, Bloco A, Ilha do Fundão, Rio de Janeiro, RJ, CEP 21941-590, Brazil
- Institute of Microbiology, Federal University of Rio de Janeiro, Macaé, RJ, Brazil
| | - Diogo A Tschoeke
- Institute of Biology and SAGE-COPPE, Federal University of Rio de Janeiro, Avenida Carlos Chagas Fo, s/n, Bloco A, Ilha do Fundão, Rio de Janeiro, RJ, CEP 21941-590, Brazil
| | - Bruno S Silva
- Institute of Biology and SAGE-COPPE, Federal University of Rio de Janeiro, Avenida Carlos Chagas Fo, s/n, Bloco A, Ilha do Fundão, Rio de Janeiro, RJ, CEP 21941-590, Brazil
| | - Koko Otsuki
- Institute of Biology and SAGE-COPPE, Federal University of Rio de Janeiro, Avenida Carlos Chagas Fo, s/n, Bloco A, Ilha do Fundão, Rio de Janeiro, RJ, CEP 21941-590, Brazil
| | - Bruno Gomez-Gil
- CIAD, AC. Mazatlan Unit for Aquaculture, AP 711, 82000, Mazatlan, Sinaloa, Mexico
| | - Jean Swings
- Institute of Biology and SAGE-COPPE, Federal University of Rio de Janeiro, Avenida Carlos Chagas Fo, s/n, Bloco A, Ilha do Fundão, Rio de Janeiro, RJ, CEP 21941-590, Brazil
| | - Fabiano L Thompson
- Institute of Biology and SAGE-COPPE, Federal University of Rio de Janeiro, Avenida Carlos Chagas Fo, s/n, Bloco A, Ilha do Fundão, Rio de Janeiro, RJ, CEP 21941-590, Brazil
| | - Cristiane C Thompson
- Institute of Biology and SAGE-COPPE, Federal University of Rio de Janeiro, Avenida Carlos Chagas Fo, s/n, Bloco A, Ilha do Fundão, Rio de Janeiro, RJ, CEP 21941-590, Brazil.
| |
Collapse
|
14
|
Curell A, Vidal L, Balibrea JM, Dopazo C, Charco R, Gómez-Gavara C. Pyogenic liver abscess: a complication after primary obesity surgery endolumenal (POSE) procedure. Surg Obes Relat Dis 2020; 16:1561-1562. [PMID: 32620377 DOI: 10.1016/j.soard.2020.05.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2020] [Revised: 05/02/2020] [Accepted: 05/05/2020] [Indexed: 11/26/2022]
Affiliation(s)
- A Curell
- Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - L Vidal
- Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | | | - C Dopazo
- Hospital Clínic de Barcelona, Barcelona, Spain
| | - R Charco
- Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | | |
Collapse
|
15
|
Vidal L, Berg R, Yang Z, Moss K. Participation of women in phase I oncology clinical trials. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz244.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
16
|
Peled A, Sarig O, Sun G, Samuelov L, Freeman A, Vidal L, Chamarthy L, Walter J, Milner J, Sprecher E. 350 Dual role of CARD14 in skin inflammatory diseases. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
Rodilla Sala E, Colomer V, Perseguer Z, Jordá A, Jordá R, Prats R, García M, Vidal L, Sanchis M, Córcoles M, Mud F, Bellver O, Adell M, Ferrer F, Hernández M, Llopis T, Rodrigo M, Baixauli V, Climent M, Moreno L. DIFFERENCES IN AORTIC AUGMENTATION PRESSURE BETWEEN NORMOTENSIVE AND HYPERTENSIVE SUBJECTS MEASURED IN COMMUNITY PHARMACIES IN SPAIN. J Hypertens 2019. [DOI: 10.1097/01.hjh.0000572696.06657.f1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
18
|
Panciroli C, Lucente G, Vidal L, Carcereny E, Quiroga V, Pardo JC, Romeo M, Estival A, Manzano JL, Pardo B, Velarde JM, Esteve AM, Lopez D, Mañes A, Tuset V, Villà S, Quintero CB. Assessment of neurocognitive decline in cancer patients, except brain cancer, under long-term treatment with bevacizumab. Clin Transl Oncol 2019; 22:411-419. [PMID: 31144211 DOI: 10.1007/s12094-019-02143-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Accepted: 05/21/2019] [Indexed: 11/25/2022]
Abstract
PURPOSE We performed a cross-sectional study of neurocognitive function in non-brain cancer patients treated with long-term bevacizumab. METHODS/PATIENTS From 2015 to 2017, we included patients with different types of cancer treated with bevacizumab with or without chemotherapy (BEV; N = 20) or only chemotherapy (ChT; N = 19) for at least 34 weeks, patients who received non-brain radiotherapy (RxT; N = 19), and healthy controls (HC; N = 19) were assessed once at week 34 of treatment (BEV and ChT) or at completion of radiotherapy. Neurocognition was evaluated with the Hopkins Verbal Learning Test-Revised (HVLT-R) total and delayed recall, the Trail Making Test A and B, and the Controlled Oral Word Association Test in the four groups. Non-parametric tests were used to assess differences between groups. RESULTS The BEV, ChT, and RxT groups scored significantly lower than the HC group on all tests and especially on the HVLT-R total recall. In no case were the mean scores of the BEV group significantly lower than those of the ChT or RxT groups. CONCLUSIONS Neurocognitive impairment was seen even in patients treated with local non-brain radiotherapy. Treatment with bevacizumab for a long period of time does not seem to worsen neurocognitive function to a greater extent than chemotherapy.
Collapse
Affiliation(s)
- C Panciroli
- Badalona Applied Research Group in Oncology (B-ARGO Group) - Institut Investigació Germans Trias i Pujol (IGTP), Hospital Germans Trias i Pujol - Institut Catalá d'Oncologia (ICO), Badalona, Barcelona, Spain
- University of Barcelona (UB), Barcelona, Spain
| | - G Lucente
- Neurology Service - Neuroscience Department, Hospital Germans Trias i Pujol - Institut Investigació Germans Trias i Pujol (IGTP), Badalona, Barcelona, Spain
- Universitat Automa de Barcelona (UAB), Bellaterra, Barcelona, Spain
| | - L Vidal
- Medical Oncology Service, Hospital Clinic de Barcelona, Barcelona, Spain
| | - E Carcereny
- Medical Oncology Service - Badalona Applied Research Group in Oncology (B-ARGO Group), Hospital Germans Trias i Pujol - Institut Catalá d'Oncologia (ICO), Badalona, Barcelona, Spain
| | - V Quiroga
- Medical Oncology Service - Badalona Applied Research Group in Oncology (B-ARGO Group), Hospital Germans Trias i Pujol - Institut Catalá d'Oncologia (ICO), Badalona, Barcelona, Spain
| | - J C Pardo
- Medical Oncology Service - Badalona Applied Research Group in Oncology (B-ARGO Group), Hospital Germans Trias i Pujol - Institut Catalá d'Oncologia (ICO), Badalona, Barcelona, Spain
| | - M Romeo
- Medical Oncology Service - Badalona Applied Research Group in Oncology (B-ARGO Group), Hospital Germans Trias i Pujol - Institut Catalá d'Oncologia (ICO), Badalona, Barcelona, Spain
| | - A Estival
- Medical Oncology Service - Badalona Applied Research Group in Oncology (B-ARGO Group), Hospital Germans Trias i Pujol - Institut Catalá d'Oncologia (ICO), Badalona, Barcelona, Spain
| | - J L Manzano
- Medical Oncology Service - Badalona Applied Research Group in Oncology (B-ARGO Group), Hospital Germans Trias i Pujol - Institut Catalá d'Oncologia (ICO), Badalona, Barcelona, Spain
| | - B Pardo
- Medical Oncology Service, Hospital Duran i Reynals - Institut Catalá d'Oncologia (ICO), Barcelona, Spain
| | - J M Velarde
- Medical Oncology Service - Badalona Applied Research Group in Oncology (B-ARGO Group), Hospital Germans Trias i Pujol - Institut Catalá d'Oncologia (ICO), Badalona, Barcelona, Spain
| | - A M Esteve
- Tumor Hospital Registry, Hospital Germans Trias i Pujol - Institut Catalá d'Oncologia (ICO), Badalona, Barcelona, Spain
| | - D Lopez
- Medical Oncology Service - Badalona Applied Research Group in Oncology (B-ARGO Group), Hospital Germans Trias i Pujol - Institut Catalá d'Oncologia (ICO), Badalona, Barcelona, Spain
| | - A Mañes
- Radiation Oncology Service, Hospital Germans Trias i Pujol - Institut Catalá d'Oncologia (ICO), Badalona, Barcelona, Spain
| | - V Tuset
- Radiation Oncology Service, Hospital Germans Trias i Pujol - Institut Catalá d'Oncologia (ICO), Badalona, Barcelona, Spain
| | - S Villà
- Radiation Oncology Service, Hospital Germans Trias i Pujol - Institut Catalá d'Oncologia (ICO), Badalona, Barcelona, Spain
| | - C B Quintero
- Medical Oncology Service - Badalona Applied Research Group in Oncology (B-ARGO Group), Hospital Germans Trias i Pujol - Institut Catalá d'Oncologia (ICO), Badalona, Barcelona, Spain.
| |
Collapse
|
19
|
Core J, Pham T, Bailey R, Vidal L, Bussone S, Sturchio G, LeGout J, Sharma A, Jain M, McKinney J, Ritchie C, Paz-Fumagalli R, Lewis A, Frey G, Toskich B. 03:18 PM Abstract No. 114 A single-center experience with proximal radioembolization enabled by distal angiosomal truncation (PREDATr). J Vasc Interv Radiol 2019. [DOI: 10.1016/j.jvir.2018.12.161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
20
|
Ahmed A, Paz-Fumagalli R, McKinney J, Ritchie C, Frey G, Lewis A, Devcic Z, Livingston D, Cheiky E, Vega L, Hodge D, Vidal L, Shah J, Geller B, Kolarich A, Wang M, Alvarado C, Iv C, Lubinski A, Toskich B. 03:09 PM Abstract No. 113 Lobar Yttrium-90 transarterial radioembolization equal or greater than 150Gy MIRD: an analysis of hepatic biochemical safety as a function of treated liver volume and administered dose. J Vasc Interv Radiol 2019. [DOI: 10.1016/j.jvir.2018.12.160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
21
|
Liégeois F, Eymard-Duvernay S, Boyer S, Maradan G, Kouanfack C, Domyeum J, Boyer V, Mpoudi-Ngolé E, Spire B, Delaporte E, Vidal L, Kuaban C, Laurent C. Heterogeneity of virological suppression in the national antiretroviral programme of Cameroon (ANRS 12288 EVOLCAM). HIV Med 2018; 20:38-46. [PMID: 30362279 DOI: 10.1111/hiv.12681] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/15/2018] [Indexed: 11/30/2022]
Abstract
OBJECTIVES In terms of HIV infection, western and central Africa is the second most affected region world-wide, and the gap between the regional figures for the testing and treatment cascade and the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 targets is particularly worrying. We assessed the prevalence of virological suppression in patients routinely treated in 19 hospitals in Cameroon. METHODS A cross-sectional survey was performed in adult patients receiving antiretroviral therapy (ART) in the Centre and Littoral regions. The prevalences of virological suppression (<1000 HIV-1 RNA copies/mL) were compared among all 19 hospitals using the χ2 test. Potential individual and health care-related determinants of virological suppression were assessed using multivariate logistic regression models. RESULTS A total of 1700 patients (74% women; median age 41 years; median time on ART 3.7 years) were included in the study. The prevalence of virological suppression was 82.4% overall (95% confidence interval 80.5-84.2%). It ranged from 57.1 to 97.4% according to the individual hospital (P < 0.001). After adjustment, virological suppression was associated with age, CD4 cell count at ART initiation, disclosure of HIV status to family members, interruption of ART for more than two consecutive days, and location of patient's residence and hospital (rural/urban). These factors did not explain the heterogeneity of virological suppression between the study hospitals (P < 0.001). CONCLUSIONS The overall prevalence of virological suppression was reassuring. Nevertheless, the heterogeneity of virological suppression among hospitals highlights that, in addition to programme-level data, health facility-level data are crucial in order to tailor the national AIDS programme's interventions with a view to achieving the third UNAIDS 90 target.
Collapse
Affiliation(s)
- F Liégeois
- IRD, INSERM, University of Montpellier, TransVIHMI, Montpellier, France.,CREMER, Yaoundé, Cameroon
| | - S Eymard-Duvernay
- IRD, INSERM, University of Montpellier, TransVIHMI, Montpellier, France
| | - S Boyer
- INSERM, IRD, University of Aix-Marseille, SESSTIM, Marseille, France
| | - G Maradan
- INSERM, IRD, University of Aix-Marseille, SESSTIM, Marseille, France
| | | | | | - V Boyer
- IRD, INSERM, University of Montpellier, TransVIHMI, Montpellier, France
| | | | - B Spire
- INSERM, IRD, University of Aix-Marseille, SESSTIM, Marseille, France
| | - E Delaporte
- IRD, INSERM, University of Montpellier, TransVIHMI, Montpellier, France
| | - L Vidal
- INSERM, IRD, University of Aix-Marseille, SESSTIM, Marseille, France
| | - C Kuaban
- Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon
| | - C Laurent
- IRD, INSERM, University of Montpellier, TransVIHMI, Montpellier, France
| | | |
Collapse
|
22
|
Abellán-Llobregat A, Vidal L, Rodríguez-Amaro R, Canals A, Morallón E. Evaluation of herringbone carbon nanotubes-modified electrodes for the simultaneous determination of ascorbic acid and uric acid. Electrochim Acta 2018. [DOI: 10.1016/j.electacta.2018.08.007] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
23
|
Abellán-Llobregat A, González-Gaitán C, Vidal L, Canals A, Morallón E. Portable electrochemical sensor based on 4-aminobenzoic acid-functionalized herringbone carbon nanotubes for the determination of ascorbic acid and uric acid in human fluids. Biosens Bioelectron 2018; 109:123-131. [DOI: 10.1016/j.bios.2018.02.047] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2017] [Revised: 02/13/2018] [Accepted: 02/20/2018] [Indexed: 02/07/2023]
|
24
|
Portilho-Ramos RC, Cruz APS, Barbosa CF, Rathburn AE, Mulitza S, Venancio IM, Schwenk T, Rühlemann C, Vidal L, Chiessi CM, Silveira CS. Methane release from the southern Brazilian margin during the last glacial. Sci Rep 2018; 8:5948. [PMID: 29654329 PMCID: PMC5899165 DOI: 10.1038/s41598-018-24420-0] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2017] [Accepted: 03/26/2018] [Indexed: 11/09/2022] Open
Abstract
Seafloor methane release can significantly affect the global carbon cycle and climate. Appreciable quantities of methane are stored in continental margin sediments as shallow gas and hydrate deposits, and changes in pressure, temperature and/or bottom-currents can liberate significant amounts of this greenhouse gas. Understanding the spatial and temporal dynamics of marine methane deposits and their relationships to environmental change are critical for assessing past and future carbon cycle and climate change. Here we present foraminiferal stable carbon isotope and sediment mineralogy records suggesting for the first time that seafloor methane release occurred along the southern Brazilian margin during the last glacial period (40-20 cal ka BP). Our results show that shallow gas deposits on the southern Brazilian margin responded to glacial-interglacial paleoceanographic changes releasing methane due to the synergy of sea level lowstand, warmer bottom waters and vigorous bottom currents during the last glacial period. High sea level during the Holocene resulted in an upslope shift of the Brazil Current, cooling the bottom waters and reducing bottom current strength, reducing methane emissions from the southern Brazilian margin.
Collapse
Affiliation(s)
- R C Portilho-Ramos
- MARUM - Center for Marine Environmental Sciences, University of Bremen, Leobener Strasse, 28359, Bremen, Germany. .,Programa de Pós Graduação em Geoquímica, Universidade Federal Fluminense, Outeiro São João Batista S/N, 24020-141, Niterói RJ, Brazil. .,Institute of Geosciences, University of São Paulo, Rua do Lago 562, 05508-080, São Paulo SP, Brazil.
| | - A P S Cruz
- Programa de Pós Graduação em Geoquímica, Universidade Federal Fluminense, Outeiro São João Batista S/N, 24020-141, Niterói RJ, Brazil
| | - C F Barbosa
- Programa de Pós Graduação em Geoquímica, Universidade Federal Fluminense, Outeiro São João Batista S/N, 24020-141, Niterói RJ, Brazil
| | - A E Rathburn
- Department of Geological Sciences, California State University Bakersfield, 9001 Stockdale Highway, Bakersfield, CA, USA
| | - S Mulitza
- MARUM - Center for Marine Environmental Sciences, University of Bremen, Leobener Strasse, 28359, Bremen, Germany
| | - I M Venancio
- Center for Weather Forecasting and Climate Studies (CPTEC), National Institute for Space Research (INPE), Cachoeira Paulista, Brazil
| | - T Schwenk
- MARUM - Center for Marine Environmental Sciences, University of Bremen, Leobener Strasse, 28359, Bremen, Germany
| | - C Rühlemann
- BGR - Federal Institute for Geosciences and Natural Resources, Stilleweg 2, 30655, Hannover, Germany
| | - L Vidal
- Aix-Marseille University, CNRS, IRD, CEREGE UM34, 13545, Aix-en-Provence, France
| | - C M Chiessi
- School of Arts, Sciences and Humanities, University of São Paulo, Av. Arlindo Béttio 1000, 03828-000, São Paulo SP, Brazil
| | - C S Silveira
- Programa de Pós Graduação em Geoquímica, Universidade Federal Fluminense, Outeiro São João Batista S/N, 24020-141, Niterói RJ, Brazil
| |
Collapse
|
25
|
Mayoral M, Paredes P, Saco A, Fusté P, Perlaza P, Tapias A, Fernandez-Martinez A, Vidal L, Ordi J, Pavia J, Martinez-Roman S, Lomeña F. Correlación de la captación de 18 F-FDG de la PET/TC con el Ki67 de la inmunohistoquímica en el cáncer epitelial de ovario pretratamiento. Rev Esp Med Nucl Imagen Mol 2018. [DOI: 10.1016/j.remnie.2017.10.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
26
|
Salvá P, Vidal L, Ribas M, Sáez de Ibarra J, Pericas P, Padrol D, Caldés O, Ruiz de Gopegui E, Martin J, Riera M. Experiencia en nuestro centro de endocarditis infecciosa aguda en pacientes cirróticos. Cirugía Cardiovascular 2018. [DOI: 10.1016/j.circv.2017.12.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
27
|
Vidal L, Padrol D, Salvà P, Ruiz de Gopegui E, Tarrío R, Enriquez F, Pericàs P, Ribas M, Riera M, Sáez de Ibarra J. Reparación vs sustitución valvular mitral en endocarditis infecciosa aguda. Experiencia de nuestro centro. Cirugía Cardiovascular 2018. [DOI: 10.1016/j.circv.2017.12.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
28
|
Yeshurun M, Vaxman I, Shargian L, Yahav D, Bishara J, Pasvolsky O, Wolach O, Lahav M, Gurion R, Magen H, Vidal L, Herscovici C, Peck A, Moshe M, Sela-Navon M, Naparstek E, Raanani P, Rozovski U. Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study. Clin Microbiol Infect 2017; 24:749-754. [PMID: 29208561 DOI: 10.1016/j.cmi.2017.11.019] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2017] [Revised: 11/14/2017] [Accepted: 11/22/2017] [Indexed: 11/19/2022]
Abstract
OBJECTIVES We aimed to study whether ciprofloxacin prophylaxis reduces infectious complications in patients undergoing autologous haematopoietic cell transplantation (AHCT). METHODS This is a quasi-experimental, retrospective, before-after study. We compared the incidence of bacterial-related complications among 356 patients with multiple myeloma (MM) (n = 202) and lymphoma (n = 154) who underwent AHCT with (n = 177) or without (n = 179) ciprofloxacin prophylaxis between 03/2007 and 10/2012 and between 10/2012 and 07/2016, respectively, at a single centre. RESULTS Febrile neutropaenia, bacteraemia, and pneumonia were significantly more common among patients who underwent AHCT during the second study period and did not receive antibacterial prophylaxis compared with patients who underwent AHCT during the first study period and received antibacterial prophylaxis (89.9% (161/179) vs. 83.1% (147/177), difference 6.9%, 95% CI 0-14.1%, P = 0.002; 15.1% (27/179) vs. 4.5% (8/177), difference 10.6%, 95% CI 4.4-16.9%, p < 0.0001; 12.3% (22/179) vs. 6.2% (11/177), difference 6.1%, 95% CI 0-12.3%, p = 0.04, respectively). The number-needed-to-treat to prevent one episode of bacteraemia, pneumonia, and febrile neutropaenia was 8.6, 8.5, and 13.7, respectively. Patients with ciprofloxacin prophylaxis had higher rates of ciprofloxacin-resistant bacteraemia (62.5% (5/8) vs. 18.5% (5/27), difference 44%, 95% CI 7-70%, p = 0.01). In multivariate analysis, ciprofloxacin prophylaxis significantly decreased the odds of bacteraemia (OR 0.19, 95% CI 0.07-0.52; p < 0.0001) and pneumonia (OR 0.37, 95% CI 0.16-0.85, p = 0.02). CONCLUSION According to our single-centre experience, patients with MM and lymphoma undergoing AHCT may benefit from antibacterial prophylaxis with ciprofloxacin.
Collapse
Affiliation(s)
- M Yeshurun
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
| | - I Vaxman
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - L Shargian
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - D Yahav
- Infectious Diseases Unit, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - J Bishara
- Infectious Diseases Unit, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - O Pasvolsky
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - O Wolach
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - M Lahav
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - R Gurion
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - H Magen
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - L Vidal
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - C Herscovici
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - A Peck
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel
| | - M Moshe
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel
| | - M Sela-Navon
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel
| | - E Naparstek
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - P Raanani
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - U Rozovski
- Institute of Haematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
29
|
Jaeger S, Vidal L, Kam K, Ares G. Corrigendum to “Can emoji be used as a direct method to measure emotional associations to food names? Preliminary investigations with consumers in USA and China” [Food Qual. Preference 56 (2017) 38–48]. Food Qual Prefer 2017. [DOI: 10.1016/j.foodqual.2016.11.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
30
|
Vidal L, Mangas A, Geffard M. A new therapeutic approach to auto-immune diseases: Endotherapia. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx509.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Mayoral M, Paredes P, Saco A, Fusté P, Perlaza P, Tapias A, Fernandez-Martinez A, Vidal L, Ordi J, Pavia J, Martinez-Roman S, Lomeña F. Correlation of 18F-FDG uptake on PET/CT with Ki67 immunohistochemistry in pre-treatment epithelial ovarian cancer. Rev Esp Med Nucl Imagen Mol 2017; 37:80-86. [PMID: 28869177 DOI: 10.1016/j.remn.2017.07.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2017] [Revised: 06/18/2017] [Accepted: 07/09/2017] [Indexed: 01/10/2023]
Abstract
OBJECTIVE Standardised uptake value (SUV) and volumetric parameters such as metabolic tumour volume (MTV) and total lesion glycolysis (TLG) from 18F-FDG PET/CT are useful criteria for disease prognosis in pre-operative and post-treatment epithelial ovarian cancer (EOC). Ki67 is another prognostic biomarker in EOC, associated with tumour aggressiveness. The aim of this study is to evaluate the association between 18F-FDG PET/CT measurements and Ki67 in pre-treatment EOC to determine if PET/CT parameters could non-invasively predict tumour aggressiveness. MATERIAL AND METHODS A pre-treatment PET/CT was performed on 18 patients with suspected or newly diagnosed EOC. Maximum SUV (SUVmax), mean SUV (SUVmean), whole-body MTV (wbMTV), and whole-body TLG (wbTLG) with a threshold of 30% and 40% of the SUVmax were obtained. Furthermore, Ki67 index (mean and hotspot) was estimated in tumour tissue specimens. Immunohistochemical findings were correlated with PET parameters. RESULTS The mean age was 57.0 years old (standard deviation 13.6 years). A moderate correlation was observed between mean Ki67 index and SUVmax (r=0.392), SUVmean 30% (r=0.437), and SUVmean 40% (r=0.443), and also between hotspot Ki67 index and SUVmax (r=0.360), SUVmean 30% (r=0.362) and SUVmean 40% (r=0.319). There was a weaker correlation, which was inversely negative, between mean and hotspot Ki67 and volumetric PET parameters. However, no statistical significant differences were found for any correlations. CONCLUSIONS SUVmax and SUVmean were moderately correlated with Ki67 index, whereas volumetric PET parameters overall, showed a weaker correlation. Thus, SUVmax and SUVmean could be used to assess tumour aggressiveness in pre-treatment EOC.
Collapse
Affiliation(s)
- M Mayoral
- Nuclear Medicine Department, Hospital Clínic, Barcelona, Spain
| | - P Paredes
- Nuclear Medicine Department, Hospital Clínic, Barcelona, Spain; Institut D'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.
| | - A Saco
- Department of Pathology, Hospital Clínic, Barcelona, Spain
| | - P Fusté
- Gynaecology Department, Hospital Clínic, Barcelona, Spain
| | - P Perlaza
- Nuclear Medicine Department, Hospital Clínic, Barcelona, Spain
| | - A Tapias
- Nuclear Medicine Department, Hospital Clínic, Barcelona, Spain
| | | | - L Vidal
- Medical Oncology Department, Hospital Clínic, Barcelona, Spain
| | - J Ordi
- Department of Pathology, Hospital Clínic, Barcelona, Spain; Centre de Recerca en Salut Internacional de Barcelona (CRESIB), Barcelona, Spain
| | - J Pavia
- Nuclear Medicine Department, Hospital Clínic, Barcelona, Spain; Institut D'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain; CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain
| | - S Martinez-Roman
- Institut D'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain; Gynaecology Department, Hospital Clínic, Barcelona, Spain
| | - F Lomeña
- Nuclear Medicine Department, Hospital Clínic, Barcelona, Spain; Institut D'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| |
Collapse
|
32
|
Rozental A, Gafter-Gvili A, Vidal L, Raanani P, Gurion R. The role of maintenance therapy in patients with diffuse large B-cell lymphoma: A systematic review and meta-analysis. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_85] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A. Rozental
- Hematology Division; Davidoff Cancer Center, Rabin Medical Center; Petah-Tikva Israel
| | - A. Gafter-Gvili
- Hematology Division; Davidoff Cancer Center, Rabin Medical Center; Petah-Tikva Israel
| | - L. Vidal
- Hematology Division; Davidoff Cancer Center, Rabin Medical Center; Petah-Tikva Israel
| | - P. Raanani
- Hematology Division; Davidoff Cancer Center, Rabin Medical Center; Petah-Tikva Israel
| | - R. Gurion
- Hematology Division; Davidoff Cancer Center, Rabin Medical Center; Petah-Tikva Israel
| |
Collapse
|
33
|
Amitai I, Gurion R, Vidal L, Dann E, Raanani P, Gafter-Gvili A. PET-CT-adapted therapy for advanced Hodgkin lymphoma: A systematic review of the literature. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- I. Amitai
- Institute of Hematology; Rabin Medical Center; Petah Tikva Israel
| | - R. Gurion
- Institute of Hematology; Rabin Medical Center; Petah Tikva Israel
| | - L. Vidal
- Institute of Hematology; Rabin Medical Center; Petah Tikva Israel
| | - E.J. Dann
- Department of Hematology and Bone Marrow Transplantation; Rambam Health Care Campus; Haifa Israel
| | - P. Raanani
- Institute of Hematology; Rabin Medical Center; Petah Tikva Israel
| | - A. Gafter-Gvili
- Institute of Hematology; Rabin Medical Center; Petah Tikva Israel
| |
Collapse
|
34
|
Gurion R, Bernstein H, Vidal L, Raanani P, Gafter-Gvili A. THE VALUE OF PET/CT IN DETECTING BONE MARROW INVOLVEMENT IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- R. Gurion
- Hematology Institute; Rabin Medical Center; Petach Tikva Israel
| | - H. Bernstein
- Department of Nuclear Medicine; Rabin Medical Center; Petach Tikva Israel
| | - L. Vidal
- Hematology Institute; Rabin Medical Center; Petach Tikva Israel
| | - P. Raanani
- Hematology Institute; Rabin Medical Center; Petach Tikva Israel
| | - A. Gafter-Gvili
- Hematology Institute; Rabin Medical Center; Petach Tikva Israel
| |
Collapse
|
35
|
Abellán-Llobregat A, Jeerapan I, Bandodkar A, Vidal L, Canals A, Wang J, Morallón E. A stretchable and screen-printed electrochemical sensor for glucose determination in human perspiration. Biosens Bioelectron 2017; 91:885-891. [PMID: 28167366 PMCID: PMC5328638 DOI: 10.1016/j.bios.2017.01.058] [Citation(s) in RCA: 165] [Impact Index Per Article: 23.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2016] [Revised: 01/13/2017] [Accepted: 01/25/2017] [Indexed: 02/08/2023]
Abstract
Here we present two types of all-printable, highly stretchable, and inexpensive devices based on platinum (Pt)-decorated graphite for glucose determination in physiological fluids. Said devices are: a non-enzymatic sensor and an enzymatic biosensor, the latter showing promising results. Glucose has been quantified by measuring hydrogen peroxide (H2O2) reduction by chronoamperometry at -0.35V (vs pseudo-Ag/AgCl) using glucose oxidase immobilized on Pt-decorated graphite. The sensor performs well for the quantification of glucose in phosphate buffer solution (0.25M PBS, pH 7.0), with a linear range between 0 mM and 0.9mM, high sensitivity and selectivity, and a low limit of detection (LOD). Thus, it provides an alternative non-invasive and on-body quantification of glucose levels in human perspiration. This biosensor has been successfully applied on real human perspiration samples and results also show a significant correlation between glucose concentration in perspiration and glucose concentration in blood measured by a commercial glucose meter.
Collapse
Affiliation(s)
- A Abellán-Llobregat
- Instituto Universitario de Materiales, Universidad de Alicante, Apartado 99, 03080 Alicante, Spain
| | - Itthipon Jeerapan
- Department of NanoEngineering, University of California, La Jolla, San Diego, CA 92093, USA
| | - A Bandodkar
- Department of NanoEngineering, University of California, La Jolla, San Diego, CA 92093, USA
| | - L Vidal
- Departamento de Química Analítica, Nutrición y Bromatología and Instituto Universitario de Materiales, Universidad de Alicante, Apartado 99, 03080 Alicante, Spain
| | - A Canals
- Departamento de Química Analítica, Nutrición y Bromatología and Instituto Universitario de Materiales, Universidad de Alicante, Apartado 99, 03080 Alicante, Spain
| | - J Wang
- Department of NanoEngineering, University of California, La Jolla, San Diego, CA 92093, USA
| | - E Morallón
- Instituto Universitario de Materiales, Universidad de Alicante, Apartado 99, 03080 Alicante, Spain
| |
Collapse
|
36
|
Abellán-Llobregat A, Vidal L, Rodríguez-Amaro R, Berenguer-Murcia Á, Canals A, Morallón E. Au-IDA microelectrodes modified with Au-doped graphene oxide for the simultaneous determination of uric acid and ascorbic acid in urine samples. Electrochim Acta 2017. [DOI: 10.1016/j.electacta.2016.12.132] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
37
|
Alfon J, Vidal L, Gaba L, Victoria I, Gil M, Laquente B, Brunet M, Colom H, Ramis J, Perez-Montoyo H, Cortal M, Gomez-Ferreria M, Muñoz P, Erazo T, Lizcano J, Domenech C, Gascon P. Determination of recommended phase II dose of ABTL0812, a novel regulator of Akt/mTOR axis, by pharmacokinetic-pharmacodynamic modelling. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.21] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Vidal L, Joussein E, Colas M, Cornette J, Sanz J, Sobrados I, Gelet JL, Absi J, Rossignol S. Controlling the reactivity of silicate solutions: A FTIR, Raman and NMR study. Colloids Surf A Physicochem Eng Asp 2016. [DOI: 10.1016/j.colsurfa.2016.05.039] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
39
|
Stanovici J, Le Nail LR, Brennan MA, Vidal L, Trichet V, Rosset P, Layrolle P. Bone regeneration strategies with bone marrow stromal cells in orthopaedic surgery. Curr Res Transl Med 2016; 64:83-90. [PMID: 27316391 DOI: 10.1016/j.retram.2016.04.006] [Citation(s) in RCA: 57] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2016] [Revised: 04/13/2016] [Accepted: 04/14/2016] [Indexed: 12/18/2022]
Abstract
Bone is the most transplanted tissue human with 1 million procedures every year in Europe. Surgical interventions for bone repair are required for varied reasons such as trauma resulting non-union fractures, or diseases including osteoporosis or osteonecrosis. Autologous bone grafting is the gold standard in bone regeneration but it requires a second surgery with associated pain and complications, and is also limited by harvested bone quantity. Synthetic bone substitutes lack the osteoinductive properties to heal large bone defects. Cell therapies based on bone marrow or ex vivo expanded mesenchymal stromal stem cells (MSCs) in association with synthetic calcium phosphate (CaP) bone substitutes may be alternatives to autologous bone grafting. This manuscript reviews the different conventional biological and synthetic bone grafting procedures as well as the more recently introduced cell therapy approaches used in orthopaedic surgery for bone regeneration. Some clinical studies have demonstrated safety and efficacy of these approaches but regeneration of large bone defects remain challenging due to the absence of rapid and adequate vascularisation. Future directions in the field of bone regeneration are presented, such as testing alternative cell sources or in situ fabrication of vascularized bone grafts in patients.
Collapse
Affiliation(s)
- J Stanovici
- Inserm, UMR 957, équipe labellisée Ligue 2012, 1, rue Gaston-Veil, 44035 Nantes, France; Laboratoire de physiopathologie de la résorption osseuse et thérapie des tumeurs osseuses primitives, faculté de médecine, université de Nantes, Nantes Atlantique universités, 1, rue Gaston-Veil, 44035 Nantes, France; Service de chirurgie orthopédique et traumatologique 2, hôpital Trousseau, CHRU de Tours, 37044 Tours, France
| | - L-R Le Nail
- Inserm, UMR 957, équipe labellisée Ligue 2012, 1, rue Gaston-Veil, 44035 Nantes, France; Laboratoire de physiopathologie de la résorption osseuse et thérapie des tumeurs osseuses primitives, faculté de médecine, université de Nantes, Nantes Atlantique universités, 1, rue Gaston-Veil, 44035 Nantes, France; Service de chirurgie orthopédique et traumatologique 2, hôpital Trousseau, CHRU de Tours, 37044 Tours, France
| | - M A Brennan
- Inserm, UMR 957, équipe labellisée Ligue 2012, 1, rue Gaston-Veil, 44035 Nantes, France; Laboratoire de physiopathologie de la résorption osseuse et thérapie des tumeurs osseuses primitives, faculté de médecine, université de Nantes, Nantes Atlantique universités, 1, rue Gaston-Veil, 44035 Nantes, France
| | - L Vidal
- Inserm, UMR 957, équipe labellisée Ligue 2012, 1, rue Gaston-Veil, 44035 Nantes, France; Laboratoire de physiopathologie de la résorption osseuse et thérapie des tumeurs osseuses primitives, faculté de médecine, université de Nantes, Nantes Atlantique universités, 1, rue Gaston-Veil, 44035 Nantes, France
| | - V Trichet
- Inserm, UMR 957, équipe labellisée Ligue 2012, 1, rue Gaston-Veil, 44035 Nantes, France; Laboratoire de physiopathologie de la résorption osseuse et thérapie des tumeurs osseuses primitives, faculté de médecine, université de Nantes, Nantes Atlantique universités, 1, rue Gaston-Veil, 44035 Nantes, France
| | - P Rosset
- Inserm, UMR 957, équipe labellisée Ligue 2012, 1, rue Gaston-Veil, 44035 Nantes, France; Laboratoire de physiopathologie de la résorption osseuse et thérapie des tumeurs osseuses primitives, faculté de médecine, université de Nantes, Nantes Atlantique universités, 1, rue Gaston-Veil, 44035 Nantes, France; Service de chirurgie orthopédique et traumatologique 2, hôpital Trousseau, CHRU de Tours, 37044 Tours, France
| | - P Layrolle
- Inserm, UMR 957, équipe labellisée Ligue 2012, 1, rue Gaston-Veil, 44035 Nantes, France; Laboratoire de physiopathologie de la résorption osseuse et thérapie des tumeurs osseuses primitives, faculté de médecine, université de Nantes, Nantes Atlantique universités, 1, rue Gaston-Veil, 44035 Nantes, France; Service de chirurgie orthopédique et traumatologique 2, hôpital Trousseau, CHRU de Tours, 37044 Tours, France.
| |
Collapse
|
40
|
Mayoral M, Fernandez-Martinez A, Vidal L, Fuster D, Aya F, Pavia J, Pons F, Lomeña F, Paredes P. Prognostic value of 18 F-FDG PET/CT volumetric parameters in recurrent epithelial ovarian cancer. Rev Esp Med Nucl Imagen Mol 2016. [DOI: 10.1016/j.remnie.2016.01.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
41
|
Partovi S, Vidal L, Nakamoto D, Lu Z, Buethe J, Coffey M, Patel I. Lymphatic malformation treatment in adult and pediatric populations using real-time MRI guided percutaneous sclerotherapy. J Vasc Interv Radiol 2016. [DOI: 10.1016/j.jvir.2015.12.570] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
42
|
Aguilar P, Niddam J, Vidal L, Hersant B, Bouhassira J, Bosc R, Meningaud JP. Distally based sural flap: Utility of indocyanine green in the second stage surgery. A case series. J Plast Reconstr Aesthet Surg 2016; 69:577-8. [PMID: 26803567 DOI: 10.1016/j.bjps.2015.12.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2015] [Revised: 12/06/2015] [Accepted: 12/22/2015] [Indexed: 10/22/2022]
Affiliation(s)
- P Aguilar
- Department of Plastic, Reconstructive and Aesthetic Surgery, Henri Mondor Hospital, 51 avenue du Maréchal de Lattre de Tassigny, Créteil 94010, France.
| | - J Niddam
- Department of Plastic, Reconstructive and Aesthetic Surgery, Henri Mondor Hospital, 51 avenue du Maréchal de Lattre de Tassigny, Créteil 94010, France
| | - L Vidal
- Department of Plastic, Reconstructive and Aesthetic Surgery, Henri Mondor Hospital, 51 avenue du Maréchal de Lattre de Tassigny, Créteil 94010, France
| | - B Hersant
- Department of Plastic, Reconstructive and Aesthetic Surgery, Henri Mondor Hospital, 51 avenue du Maréchal de Lattre de Tassigny, Créteil 94010, France
| | - J Bouhassira
- Department of Plastic, Reconstructive and Aesthetic Surgery, Henri Mondor Hospital, 51 avenue du Maréchal de Lattre de Tassigny, Créteil 94010, France
| | - R Bosc
- Department of Plastic, Reconstructive and Aesthetic Surgery, Henri Mondor Hospital, 51 avenue du Maréchal de Lattre de Tassigny, Créteil 94010, France
| | - J-P Meningaud
- Department of Plastic, Reconstructive and Aesthetic Surgery, Henri Mondor Hospital, 51 avenue du Maréchal de Lattre de Tassigny, Créteil 94010, France
| |
Collapse
|
43
|
Riu G, Gaba L, Victoria I, Molas G, do Pazo F, Gómez B, Creus N, Vidal L. Implementation of a pharmaceutical care programme for patients receiving new molecular-targeted agents in a clinical trial unit. Eur J Cancer Care (Engl) 2016; 27. [PMID: 26786594 DOI: 10.1111/ecc.12447] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/22/2015] [Indexed: 01/20/2023]
Abstract
A pharmaceutical care programme was implemented at our hospital in early 2013. The main objectives were to analyse and describe the pharmaceutical interventions made, to calculate adherence, interventions and to evaluate patient satisfaction with the care programme. We performed a single-centre descriptive and prospective intervention in cancer patients who received oral chemotherapy as part of a clinical trial in 2013. Eighty-three patients were included. Median age was 58 years (range, 31-80) and 42 patients (50.6%) were men. We recorded 23 interventions, 13 of which were associated with drug interactions. The mean percentage of adherence was 98.9%. The interview with the pharmacist was considered to be very important by 84.6% of the respondents. A total of 92.3% said that they would like to speak to the pharmacist at subsequent visits. The doubts detected during the visits enable us to conclude that the information patients receive with respect to their study medication is usually incomplete. An integrated pharmaceutical care programme for cancer patients participating in clinical trials with oral cytostatic drugs was successful in terms of adherence and patient satisfaction and makes it possible to guarantee the safety and effectiveness of treatment on an individual basis.
Collapse
Affiliation(s)
- G Riu
- Department of Pharmacy, Hospital Clinic Barcelona, Barcelona, Spain
| | - L Gaba
- Department of Medical Oncology, Hospital Clinic Barcelona, Barcelona, Spain
| | - I Victoria
- Department of Medical Oncology, Hospital Clinic Barcelona, Barcelona, Spain
| | - G Molas
- Department of Pharmacy, Hospital Clinic Barcelona, Barcelona, Spain
| | - F do Pazo
- Department of Pharmacy, Hospital Clinic Barcelona, Barcelona, Spain
| | - B Gómez
- Department of Pharmacy, Hospital Clinic Barcelona, Barcelona, Spain
| | - N Creus
- Department of Pharmacy, Hospital Clinic Barcelona, Barcelona, Spain
| | - L Vidal
- Department of Medical Oncology, Hospital Clinic Barcelona, Barcelona, Spain
| |
Collapse
|
44
|
Mayoral M, Fernandez-Martinez A, Vidal L, Fuster D, Aya F, Pavia J, Pons F, Lomeña F, Paredes P. Prognostic value of (18)F-FDG PET/CT volumetric parameters in recurrent epithelial ovarian cancer. Rev Esp Med Nucl Imagen Mol 2015; 35:88-95. [PMID: 26541072 DOI: 10.1016/j.remn.2015.08.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2015] [Revised: 08/07/2015] [Accepted: 08/08/2015] [Indexed: 11/25/2022]
Abstract
OBJECTIVE Metabolic tumour volume (MTV) and total lesion glycolysis (TLG) from (18)F-FDG PET/CT are emerging prognostic biomarkers in various solid neoplasms. These volumetric parameters and the SUVmax have shown to be useful criteria for disease prognostication in preoperative and post-treatment epithelial ovarian cancer (EOC) patients. The purpose of this study was to evaluate the utility of (18)F-FDG PET/CT measurements to predict survival in patients with recurrent EOC. MATERIAL AND METHODS Twenty-six patients with EOC who underwent a total of 31 (18)F-FDG PET/CT studies for suspected recurrence were retrospectively included. SUVmax and volumetric parameters whole-body MTV (wbMTV) and whole-body TLG (wbTLG) with a threshold of 40% and 50% of the SUVmax were obtained. Correlation between PET parameters and progression-free survival (PFS) and the survival analysis of prognostic factors were calculated. RESULTS Serous cancer was the most common histological subtype (76.9%). The median PFS was 12.5 months (range 10.7-20.6 months). Volumetric parameters showed moderate inverse correlation with PFS but there was no significant correlation in the case of SUVmax. The correlation was stronger for first recurrences. By Kaplan-Meier analysis and log-rank test, wbMTV 40%, wbMTV 50% and wbTLG 50% correlated with PFS. However, SUVmax and wbTLG 40% were not statistically significant predictors for PFS. CONCLUSION Volumetric parameters wbMTV and wbTLG 50% measured by (18)F-FDG PET/CT appear to be useful prognostic predictors of outcome and may provide valuable information to individualize treatment strategies in patients with recurrent EOC.
Collapse
Affiliation(s)
- M Mayoral
- Nuclear Medicine Department, Hospital Clínic, Barcelona, Spain.
| | | | - L Vidal
- Medical Oncology Department, Hospital Clínic, Barcelona, Spain
| | - D Fuster
- Nuclear Medicine Department, Hospital Clínic, Barcelona, Spain; Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - F Aya
- Medical Oncology Department, Hospital Clínic, Barcelona, Spain
| | - J Pavia
- Nuclear Medicine Department, Hospital Clínic, Barcelona, Spain; Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain
| | - F Pons
- Nuclear Medicine Department, Hospital Clínic, Barcelona, Spain; Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - F Lomeña
- Nuclear Medicine Department, Hospital Clínic, Barcelona, Spain; Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - P Paredes
- Nuclear Medicine Department, Hospital Clínic, Barcelona, Spain; Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| |
Collapse
|
45
|
Ben-Barouch S, Cohen O, Vidal L, Avivi I, Ram R. Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis. Bone Marrow Transplant 2015; 51:232-40. [PMID: 26457908 DOI: 10.1038/bmt.2015.238] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2015] [Revised: 08/27/2015] [Accepted: 08/28/2015] [Indexed: 11/09/2022]
Abstract
We aimed to evaluate the efficacy and toxicity profile of busulfan-fludarabine (Bu-Flu) compared with busulfan-cyclophosphamide (Bu-Cy) as a preparative regimen for patients undergoing allogeneic hematopoietic cell transplantation. We performed a systematic review and meta-analysis of all comparative trials, both randomized controlled trials (RCTs) and non-randomized. Our search yielded 15 trials recruiting 1830 patients. Four trials were RCTs and 11 were either one-arm intervention trials compared with historical controls or retrospective studies. There was a lower risk for non-relapse mortality (NRM) at 100 days in patients given Bu-Flu regimen compared with those given Bu-Cy regimen (relative risk (RR) 0.56; 95% confidence interval (CI) 0.34-0.92, 8 trials); however, there were no differences in all-cause mortality at 100 days (RR 0.85; 95% CI 0.56-1.30, 9 trials) and at the end of study (RR 0.81; 95% CI 0.64-1.02, 13 trials). The risks of sinusoidal obstruction syndrome (SOS) and microbiologically documented infections were lower in patients given Bu-Flu regimen (RR 0.34; 95% CI 0.19-0.62, 8 trials and RR 0.79; 95% CI 0.64-0.97, 2 trials, respectively); however, risk for SOS was no longer lower when performing sensitivity analysis according to RCTs. Engraftment kinetics, risk of grade 3-4 mucositis, GvHD, relapse and NRM at the end of the study were all similar between the two groups. We conclude that both regimens have similar efficacy profiles, whereas toxicity is lower with the Bu-Flu regimen.
Collapse
Affiliation(s)
- S Ben-Barouch
- Institute of Hematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.,Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - O Cohen
- Institute of Hematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.,Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - L Vidal
- Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.,Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel
| | - I Avivi
- Institute of Hematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.,Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - R Ram
- Institute of Hematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.,Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| |
Collapse
|
46
|
Vidal L, Calaza M, Gonzalez A. THU0013 Validation of the Association of a Functional Microsatellite in Macrophage Migration Factor with HIP OA. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.4547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
47
|
Vidal L, Joussein E, Colas M, Absi J, Rossignol S. Effect of the addition of ammonium molybdate on metakaolin-based geopolymer formation: Shrinkage and crystallization. POWDER TECHNOL 2015. [DOI: 10.1016/j.powtec.2015.02.012] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
48
|
Carloni R, Pechevy L, Isola N, Vidal L, Goga D, Watier E, Bertheuil N. [Fournier's gangrene: Cervical and facial extension. A very rare case]. ANN CHIR PLAST ESTH 2015; 61:84-9. [PMID: 25766003 DOI: 10.1016/j.anplas.2015.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2014] [Accepted: 02/09/2015] [Indexed: 10/23/2022]
Abstract
Fournier's gangrene is a fearsome disease with a bad prognosis and a mortality rate ranging between 10 and 80% according to the literature. It is extensive in 13 to 54% of cases. Up to date, cervico-facial extension has never been reported. We describe the case of a 51-year-old overweighed woman with a history of type 2 diabetes and a narrow lumbar canal who was referred to our institution for significant fatigue and increasingly painful legs. A diagnosis of Fournier's gangrene was made after correlating the physical findings with the results of a full body scan. Diffuse subcutaneous emphysema involving the face, neck, mediastinum, abdominal wall, right buttock, perineum and the right thigh was identified. Treatment included multiple surgical debridements, admission to intensive care unit, and an efficient antibiotic therapy that enabled preservation of the patient's life. To our knowledge, this is the first case of cervical and mediastinal extension of Fournier's gangrene to be reported. No clear guidelines exit on the management of this complication (cervico-facial and mediastinal drainage). We share our experience of this unusual case.
Collapse
Affiliation(s)
- R Carloni
- Service de chirurgie plastique et reconstructrice, centre des brulés, hôpital Trousseau, CHRU de Tours, avenue de la République, 37170 Chambray-les-Tours, France.
| | - L Pechevy
- Service de chirurgie plastique et reconstructrice, centre des brulés, hôpital Trousseau, CHRU de Tours, avenue de la République, 37170 Chambray-les-Tours, France
| | - N Isola
- Service de chirurgie plastique et reconstructrice, centre des brulés, hôpital Trousseau, CHRU de Tours, avenue de la République, 37170 Chambray-les-Tours, France
| | - L Vidal
- Institut de recherches médicales A.-Lanari, université de Buenos-Aires, C1427ARO Buenos-Aires, Argentine
| | - D Goga
- Service de chirurgie plastique et reconstructrice, centre des brulés, hôpital Trousseau, CHRU de Tours, avenue de la République, 37170 Chambray-les-Tours, France
| | - E Watier
- Service de chirurgie plastique et reconstructrice, hôpital Sud, CHU de Rennes, boulevard de Bulgarie, 35200 Rennes, France
| | - N Bertheuil
- Service de chirurgie plastique et reconstructrice, hôpital Sud, CHU de Rennes, boulevard de Bulgarie, 35200 Rennes, France; Inserm U917, université de Rennes 1, 35033 Rennes, France; Laboratoire SITI, établissement français du sang Bretagne, CHU de Rennes, 35033 Rennes, France; STROMAlab, UMR5273 CNRS/UPS/EFS - Inserm U1031, hôpital Rangueil, 31059 Toulouse, France
| |
Collapse
|
49
|
Vaxman I, Ram R, Gafter-Gvili A, Vidal L, Yeshurun M, Lahav M, Shpilberg O. Secondary malignancies following high dose therapy and autologous hematopoietic cell transplantation-systematic review and meta-analysis. Bone Marrow Transplant 2015; 50:706-14. [PMID: 25665042 DOI: 10.1038/bmt.2014.325] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2014] [Revised: 12/16/2014] [Accepted: 12/19/2014] [Indexed: 11/09/2022]
Abstract
We performed a systematic review and meta-analysis of randomized controlled trials comparing autologous hematopoietic cell transplantation (HCT) with other treatment modalities to analyze the risk for various secondary malignancies (SMs). Relative risks (RR) with 95% confidence intervals were estimated and pooled. Our search yielded 36 trials. The median follow-up was 55 (range 12-144) months. Overall, the RR for developing SMs was 1.23 ((0.97-1.55), I(2)=4%, 9870 patients). Subgroup analysis of trials assessing TBI-containing preparative regimens and of patients with baseline lymphoproliferative diseases, showed there was a higher risk for SMs in patients given autografts (RR=1.61 (1.05-2.48), I(2)=14%, 2218 patients and RR=1.62 (1.12-2.33), I(2)=22%, 3343 patients, respectively). Among all patients, there was a higher rate of myelodysplastic syndrome MDS/AML in patients given HCT compared with other treatments (RR=1.71 (1.18-2.48), I(2)=0%, 8778 patients). The risk of secondary solid malignancies was comparable in the short term between patients given HCT and patients given other treatments (RR=0.95 (0.67-1.32), I(2)=0%, 5925 patients). We conclude that overall the risk of secondary MDS/AML is higher in patients given autologous HCT compared with other treatments. In the subgroup of patients given a TBI-based regimen and in those with a baseline lymphoproliferative disease, there was a higher risk of overall SMs.
Collapse
Affiliation(s)
- I Vaxman
- 1] Medicine A, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel [2] Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - R Ram
- 1] Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel [2] BMT Unit, Sourasky Medical Center, Tel Aviv, Israel
| | - A Gafter-Gvili
- 1] Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel [2] Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Tel Aviv, Israel
| | - L Vidal
- 1] Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel [2] Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Tel Aviv, Israel
| | - M Yeshurun
- 1] Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel [2] Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Tel Aviv, Israel
| | - M Lahav
- 1] Medicine A, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel [2] Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - O Shpilberg
- 1] Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel [2] Institute of Hematology, Assuta Medical Center, Tel Aviv, Israel
| |
Collapse
|
50
|
Abstract
Ovarian cancer is the leading cause of death due to gynecological cancer and the 5th cause of death for cancer in women in Europe. Optimal management of patients with ovarian cancer needs the participation of a well-trained multidisciplinary team. In the last few years, we have observed a significant improvement in the knowledge of the molecular biology of the different histotypes of ovarian cancer that will probably change our standard of care in the forthcoming years. In this Guideline, we summarize the most current evidence for the medical management of ovarian cancer.
Collapse
|